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(P < 0.0002, chi-square; range from 0.5 to 6.6 events per
100 patient years) conﬁrming signiﬁcant heterogeneity in
the results. In the assembled cohort of 3998 patients there
were 174 admissions in 6 months, of which 117 included
some evidence of warfarin related bleeding. Applying the
criteria from the 12 different studies resulted in a range
of 24 to 117 of these events being classiﬁed as “major
bleeds”. The 3 studies with most restrictive deﬁnitions
reported from 0.5 to 1.1 events per 100 patient years,
compared with from 1.5 to 2.8 events per 100 patient
years for the 4 studies with least restrictive deﬁnitions.
CONCLUSIONS: It is essential for future outcomes
research in anticoagulant therapy that consistent deﬁni-
tions of major adverse outcomes are applied. The in-
consistent deﬁnitions used in the 12 published studies
reviewed make it impossible to assess the impact of other
differences between studies, for example in INR range or
% of time within range.
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EFFECTIVENESS OF CLINICAL PATHWAYS FOR
PATIENTS WITH HEART FAILURE
Panella M, Marchisio S
University of Eastern Piedmont “A. Avogadro”, Novara, Italy
OBJECTIVES: To evaluate the effectiveness of the care
provided to patients with heart failure through the im-
plementation of clinical pathways at the hospital “The
Holy Family” in Novafeltria (Italy). METHODS: We per-
formed a pre-post analysis model to evaluate the effect of
the application of clinical pathways on process indicators,
outcome indicators and on the costs sustained to treat the
patients. We compared the results obtained treating the
patients according to the clinical pathway with the results
obtained before implementing the pathway. We studied
quantitative variables with t Student test or Wilcoxon
test, qualitative variables with X2 test. RESULTS: Two
hundred forty-six cases were included in our study. These
subjects were all the patients admitted for hearth failure
to the hospital and treated by the staff. We compared the
age, the sex and the disease staging (NYHA scores at
admission) of the patients of the 2 groups and we did not
ﬁnd any signiﬁcant difference. After the implementation
of the pathway we observed a signiﬁcant improvement of
the core processes. We observed a reduction of the rate
unscheduled readmissions within 31 days from discharge
(from 6.74% to 2.94%; p > 0.05), of the average length
of stay (from 10.89 days to 7.86; p < 0.05) and of inpa-
tients’ mortality (from 17.42% to 4.41%; p < 0.01). The
average costs for patient increased from 2.399 US$ 
to 2.596 US$ (p > 0.05). CONCLUSION: Our primary
ﬁnding was that the implementation of the clinical
pathway for heart failure improved patients’ outcomes
and the quality of the core processes. Our results also
showed that this was possible without incrementing the
costs. This study has important limitations too. The initial
measurement occurred a year before the full implemen-
tation of the pathways. Thus, it is possible that some of
the observed improvement represented a natural drift
toward higher performance.
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BY HYPERCHOLESTEROLAEMIC PATIENTS
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TO ATORVASTATIN, PRAVASTATIN OR
SIMVASTATIN: AN EVIDENCE-BASED 
MEDICINE APPROACH
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OBJECTIVE: To determine the number needed to treat
(NNT) for one additional patient to achieve the European
Atherosclerosis Society (EAS) target for LDL-C of <3
mmol/L at 12 weeks for rosuvastatin compared to ator-
vastatin, pravastatin or simvastatin. Patients included in
the clinical trials comparing rosuvastatin with ator-
vastatin, pravastatin and simvastatin had an initial 
LDL-C ≥160 (4.1mmol/L) and <250mg/dL (6.5mmol/L).
METHODS: The rosuvastatin trials were speciﬁcally
designed to allow pooling of the data to provide summary
estimates of efﬁcacy. This design strategy minimised the
potential bias caused when pooling results by variation in
the event rates, differences in the outcomes considered,
effects of secular trends on disease risk, and differences
in clinical setting. The pooled efﬁcacy data was used as
the basis for the calculation of the NNTs. RESULTS:
Rosuvastatin 10mg is more effective at lowering LDL-C
to the EAS target than atorvastatin 10mg, pravastatin 20
mg and simvastatin 20mg at 12 weeks and this translates
into relatively small NNTs. By convention, NNTs are
rounded up to the nearest whole number of patients.
Rosuvastatin 10mg has an NNT of 4 compared to ator-
vastatin 10mg, 2 compared to pravastatin 20mg, and 4
compared to simvastatin 20mg (p < 0.001, all compar-
isons). CONCLUSIONS: As a general rule, an NNT of 6
or less might be considered “good” for an acute treat-
ment, while an NNT as large as 40 might be considered
“good” for a chronic treatment (depending on the dura-
tion of treatment and the severity of outcome). In this
context, an NNT of 4 for rosuvastatin 10mg compared
to the next best in class (atorvastatin 10mg) would be
considered a very favourable result.
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OBJECTIVES: Enoxaparin has been used for thrombo-
prophylaxis (TBX) when patients with mechanical heart
valves require bridging therapy for sub-therapeutic
chronic oral anticoagulation (COA). Due to recent
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reports of prosthetic heart valve thromboses while on
enoxaparin, the medication is no longer recommended 
for this indication. The objective of this research was to
examine the relationship between the use of enoxaparin
for TBX in patients with mechanical heart valves and
negative health outcomes. METHODS: Data were retro-
spectively obtained from a hospital-based anticoagulation
clinic database between January 1998 and July 2002.
RESULTS: Twenty patients (13 mitral valve replacement
[MVR], 6 aortic valve replacement [AVR], and 1 combi-
nation [MVR/AVR]) representing 36 encounters were
identiﬁed. Eighteen patients had multiple co-morbid 
conditions that further increased their risk for thrombus
formation including: atrial ﬁbrillation, congestive heart
failure, previous stroke, and cancer. All patients received
enoxaparin 1mg/kg every 12 hours. Enoxaparin was used
for TBX as bridging therapy associated with sub-optimal
COA. Reasons for a sub-optimal anticoagulation with
warfarin included non-adherence to warfarin therapy
and/or a low vitamin K diet, or a suboptimal dose of 
warfarin. In 35 of 36 patient encounters, no evidence of
thromboembolic events occurred during bridging therapy
with enoxaparin. One patient developed left hemian-
opsia and blurred vision approximately 3–4 hours after
beginning enoxaparin therapy. Prior to beginning enoxa-
parin therapy, the patient’s INR was 1.39; the duration
of sub-therapeutic COA in this patient is unknown. It
could not be determined if this event was due to an inad-
equate level of anticoagulation provided by enoxaparin
or inadequate anticoagulation with warfarin prior to
receiving enoxaparin. CONCLUSION: Enoxaparin was
an effective agent for thromboprophylaxis in patients
with mechanical heart valves requiring bridging therapy
for sub-therapeutic chronic oral anticoagulation in this
population. Further research is required to conﬁrm these
ﬁndings.
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OBJECTIVES: Prior studies have shown that wide vari-
ations in the management of hypertension among differ-
ent racial groups exist. The objective of our study is to
explore the racial variations in the utilization of different
classes of antihypertensive pharmaceuticals after adjust-
ing for confounding factors. METHODS: We identiﬁed
2692 individuals diagnosed with hypertension from 1998
MEPS Household Component by their ICD-9 code. The
use of antihypertensive medications were classiﬁed into
six categories and one no treatment category. Logistic
regressions were used to adjust for demographics, socioe-
conomic status, insurance, and coexisting diseases. Odds
ratios, conﬁdence intervals (CI), and signiﬁcance levels
were reported. RESULTS: Compared with Caucasian
people, African-American and Hispanic individuals with
hypertension were at signiﬁcantly higher risk of receiving
no antihypertensive medication therapy (OR: 1.39, CI:
1.13–1.71), and (OR: 1.41, CI: 1.10–1.80), respectively,
even after controlling for potential confounders. Within
different classes of antihypertensive medications, African
Americans had signiﬁcantly lower use of Beta-blockers 
or ACE inhibitors as monotherapy (OR: 0.41, CI:
0.27–0.61) and (OR: 0.50, CI: 0.34–0.75) respectively.
This ﬁnding is consistent with hypertension treatment
guidelines recommended by the Fifth Joint National
Committee on the Detection, Evaluation, and Treatment
of High Blood Pressure. Individuals with coexisting dis-
eases, including diabetes (OR: 1.51, CI: 1.24–1.85), con-
gestive heart failure (OR: 5.11, CI: 3.06–8.53), angina
(OR: 2.65, CI: 1.57–4.50), and renal diseases (OR: 2.74,
CI: 1.17–6.44) had substantially higher rates of receiv-
ing combination therapy. CONCLUSIONS: Substantial
racial variations in the utilization of antihypertensive
medications can not simply be explained by demographic
and socioeconomic differences across different racial
groups. Efforts should be made to improve the medica-
tion treatment rate of hypertension among African 
Americans and Hispanics.
PCV15
W
IT
HD
RA
W
N
